CergenX, a MedTech firm based in Cork, has successfully secured €1.2m in funding for its groundbreaking product, the Newborn Brain Screener. This innovative device utilizes AI technology to enable non-specialists to screen newborns for brain injury in less than 15 minutes.
The funding, raised through a private financing round with high net worth individuals and previous investor Enterprise Ireland, will be allocated towards further device development and the recruitment of professionals in AI, product management, and software engineering.
The Newborn Brain Screener is currently awaiting regulatory approval and is projected to be launched in 2025.
Led by CEO Jason Mowles, CSO Professor Geraldine Boylan, and CTO Sean Griffin, CergenX’s breakthrough in brain injury screening holds the potential to significantly improve early detection and treatment for infants, ultimately leading to enhanced long-term outcomes.
Product Overview
The Newborn Brain Screener developed by MedTech firm CergenX is an innovative product that utilizes artificial intelligence to enable non-specialists to efficiently screen newborns for brain injury in less than 15 minutes.
This groundbreaking device aims to address the critical need for early detection and intervention in infants at risk of brain injury. By incorporating AI technology, the Newborn Brain Screener can analyze complex data and provide accurate assessments, allowing healthcare professionals to make informed decisions regarding further diagnostic testing or immediate intervention.
This device has the potential to revolutionize the screening process, significantly reducing the time and resources required for early detection. As regulatory approval is anticipated next year and release scheduled for 2025, the Newborn Brain Screener holds promise for improving the outcomes of infants at risk of brain injury.
Company Information
Founded in 2021, the Cork-based MedTech firm specializes in developing a product that utilizes AI to screen newborns for brain injury in a timely manner.
The company’s Newborn Brain Screener aims to provide a solution that allows non-specialists to accurately detect brain injuries in babies within 15 minutes.
Led by CEO Jason Mowles, CergenX has garnered €1.2m in funding through a private financing round, with high net worth individuals and previous investor Enterprise Ireland participating.
This funding will be instrumental in further developing the Newborn Brain Screener and expanding the team by hiring professionals in AI, product management, and software engineering.
As a spin-out from the Infant Centre in UCC, CergenX is poised to make a significant impact in the field of infant healthcare, providing a revolutionary screening device that can potentially improve early detection and intervention for brain injuries in newborns.
Future Development Plans
Scheduled for regulatory approval next year and release in 2025, the MedTech firm’s product aims to provide a timely and accurate screening solution for brain injuries in newborns, potentially improving early detection and intervention in infant healthcare.
The future development plans of CergenX include further refinement and enhancement of their Newborn Brain Screener. The recently raised funding of €1.2m will be utilized for these purposes, as well as for hiring professionals specialized in AI, product management, and software engineering.
By leveraging AI technology, the company’s product enables non-specialists to screen newborns for brain injuries in less than 15 minutes. This could significantly enhance the screening process and expedite the identification of potential brain injuries, leading to more effective and timely interventions.
The company’s commitment to continuous innovation and improvement positions them as a key player in the field of infant healthcare.
